WithdrawnNCT03290963

Lithium for treatment-resistant depression

This study was withdrawn in the United States. It is testing lithium for treatment-resistant depression.

DepressionDrugFrom 18 Years to 64 Years

The study in practice

Understand this study

This study is for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: November 30, 2017

Recruitment status: Withdrawn
Enrollment listed in the registry: 0
Sponsor: William V. Bobo, M.D.
Sponsor type: Individual investigator
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 64 Years
Official registry ID: NCT03290963
Official title: Targeting mTOR/GSK3 With Lithium Augmentation to Enhance and Sustain Rapid Antidepressant Actions of Ketamine in Adults With Treatment-Resistant Depression: A Precision Medicine Approach for Psychiatry

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT03290963. We help you review the study, but cannot decide medical eligibility.

Withdrawn

Rochester, United States

Compensation and expense reimbursement have not been verified for this summary.

FAQ

Who is behind this study?

The study sponsor is William V. Bobo, M.D.

Does this study involve medication?

Yes. The study involves medication, including lithium, Placebo and ketamine.

Who can participate?

This study is for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.